J&J, Roche among companies selected for FDA digital health pilot

The regulator hopes to improve how it reviews digital medical devices, aiming to streamline the path to market for new health tools.

Filed under: Company

5 questions: making Multiple Sclerosis care more patient-centric

Trishna Bharadia, Multiple Sclerosis patient advocate, wants to make MS care more patient-centric.
The post 5 questions: making Multiple Sclerosis care more patient-centric appeared first on Pharmaphorum.

Filed under: MS

AstraZeneca, NewLink pen PD-L1 and IDO combination pact

AstraZeneca has struck a deal to combine its anti-PD-L1 drug with NewLink Genetics’ IDO pathway inhibitor. The collaborators will jointly fund a phase 2 trial of the combination in pancreatic cancer patients.

Filed under: Cancer, Immunotherapy

Novartis’ CAR-T drug needs new payment model, says Express Scripts

Cost of Novartis’ revolutionary therapy is obstacle, says CMO.
The post Novartis’ CAR-T drug needs new payment model, says Express Scripts appeared first on Pharmaphorum.

Filed under: Payer

How Startups Are Trying To Overcome India’s Healthcare Challenges

As Health Care Industry is projected to grow by 17% (compounded annual growth rate) by 2020; startups are attempting to overcome problems such as poor health infrastructure, low levels of insurance, and rural vs urban disparity that are plaguing health services in India.

Filed under: Emerging Markets

New Infographic: A Response to “A Better Deal” on Drug Pricing

The United States is the global leader in biomedical innovation, discovering more new cures than …

Filed under: Pricing

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

The positive results in the clinical trial help validate Alnylam’s $7 billion market valuation and pave the way for more drugs based on RNAi technology.

Filed under: Company

Bristol, Roche tap Halozyme for tech platform

Between upfront, milestone and royalty payments, the separate licensing agreements could be worth more than $2 billion combined.

Filed under: Company

Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance

At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx (secukinumab) evidencing its long term skin clearance benefits and safety profile in the treatment of psoriasis.
read more

Filed under: Inflammatory

Precision Therapy Proves Effective in Treatment-Resistant Subgroup of COPD Patients

NewsCOPD, a progressive lung disease characterized by airway obstruction and chronic lung inflammation, affects 30 million Americans.Contributed Author: University of Pittsburgh School of Health SciencesTopics: Drug Discovery

Filed under: COPD

Fitbit and Dexcom to bring diabetes data to Ionic smartwatch

Dexcom G5 Mobile data will be displayed on Fitbit’s Ionic smartwatch.
The post Fitbit and Dexcom to bring diabetes data to Ionic smartwatch appeared first on Pharmaphorum.

Filed under: Diabetes

Gilead aims to expand CAR-T manufacturing capabilities post-Kite acquisition

Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn.

Filed under: Cancer, Immunotherapy

Boehringer’s Humira biosimilar wins US green light

US regulators have approved Boehringer Ingelheim’s Cyltezo, a biosimilar to AbbVie’s Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases.

Filed under: Biosimilar

Propeller Health Expands Digital Health R&D Partnership with GSK

NewsThe Propeller platform has been used by patients and physicians in over 55 commercial programs across the United States.Contributed Author: Propeller HealthTopics: Biotech

Filed under: R&D

AstraZeneca touts Brilinta CV benefit with new analysis

Days before the European Society of Cardiology’s 2017 Congress, the British pharma said an analysis of a prior study showed the drug lowered risk of cardiovascular death.

Filed under: Cardiovascular

Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones

EAST HANOVER, N.J., Aug. 21, 2017 /PRNewswire/ — Novartis announced today the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone, without the need for clinic visits. The study, Evaluation of Evidence from Smart Phone Sensors…

Filed under: MS

On Drug Pricing: FDA Backs Up Its Calls for Increased Competition

FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Recently, the agency he oversees took some unusual steps to back up those statements with action. Last week, the FDA approved the use […]

Filed under: Pricing

AstraZeneca ups investment in messenger RNA drugs with Ethris deal

FRANKFURT (Reuters) – AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.

Filed under: Company

Amgen And Humana Partner For Improved Health Outcomes And Efficiency

THOUSAND OAKS, Calif. and LOUISVILLE, Ky., Aug. 17, 2017 /PRNewswire/ — Two of the nation’s leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to identify opportunities to improve health…

Filed under: Company

Biogen’s Alzheimer’s Hope Tops The Sector’s Most Valuable Pipeline Projects

Filed under: Alzheimer’s